Arbutus Biopharma
ABUS
ABUS
165 hedge funds and large institutions have $536M invested in Arbutus Biopharma in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
2% more funds holding
Funds holding: 162 → 165 (+3)
0.03% less ownership
Funds ownership: 61.67% → 61.64% (-0.03%)
4% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 53
Holders
165
Holding in Top 10
5
Calls
$12.5M
Puts
$3.26M
Top Buyers
| 1 | +$11.1M | |
| 2 | +$2.65M | |
| 3 | +$2.49M | |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$2.31M |
| 5 |
Morgan Stanley
New York
|
+$1.31M |
Top Sellers
| 1 | -$3.93M | |
| 2 | -$3.31M | |
| 3 | -$2.74M | |
| 4 |
SCM
Saba Capital Management
New York
|
-$2.64M |
| 5 |
FC
Foursixthree Capital
New York
|
-$2.63M |
